Frameshift events predict anti–PD-1/L1 response in head and neck cancer

Glenn J. Hanna(Dana-Farber Cancer Institute), Robert I. Haddad(Dana-Farber Cancer Institute)

JCI Insight

February 21, 2018

10.1172/jci.insight.98811

Cited by 276

Related Papers

Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

|Journal of the National Comprehensive Cancer Network|2022|495

Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma

|JAMA Oncology|2020|340

A Phase II Clinical and Pharmacodynamic Study of E7070 in Patients with Metastatic, Recurrent, or Refractory Squamous Cell Carcinoma of the Head and Neck

|Clinical Cancer Research|2004|67